| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| “XPORT” – ENGOT-EN20/GOG-3083/XPORT-EC-042 | 22-08 | p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma. When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control). So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed. |
The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| 22-09 ADEPPT | 22-09 | Lung caner patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status[Cohort 1] or Elderly (≥70 years) [Cohort 2] |
The purpose of the trial is to assess the clinical efficacy of adagrasib treatment in patients with KRASG12C-mutant NSCLC, in patients who are elderly (≥70 years) or those with poor performance status (ECOG PS=2). |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AFFIRM-AL | 22-13 | The target population for this study are Mayo Stage IV AL amyloid patients |
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ALLTogether | 20-09 | Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia |
ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ANTHOS ANT 007 – Aster | 24-11 | Cancer Associated Venous Thromboembolism |
The purpose of this study is to compare the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ANTHOS ANT 008 – Magnolia | 24-12 | Gastrointestinal (GI)/genitourinary (GU) cancer associated VTE |
The purpose of this study is to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE. |
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| BCBI | 24-13 | Blood Cancer |
|
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| BD – Bone Marrow/Blood | Healthy Volunteers for Research and Development Purpose |
|
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BD CHaPTeR | 24-26 | Clinical Haematology Patients |
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| Beigene 311-308 / MAHOGANY | 24-30 | Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
|
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BRAND | 23-11 | Non-Small Cell Lung Cancer |
The main purpose of this study is see if EBC(Exhaled Breath Condensate) can be used to check for biomarkers which are associated with a radiologic response to chemoimmunotherapy for patients with advanced NSCLC |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BRUIN CLL-322 | 20-21-44 | Previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma |
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. |
| Name | No. | For Patients with | Purpose | |
|---|---|---|---|---|
| CA057-001 | CA057-001 | Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. |
|
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA058-1019 | CA058-1019 | Relapsed or refractory multiple myeloma who have already had 2 to 3 lines of MM therapy, including a drug called lenalidomide and a drug from a class called anti-CD38 antibodies. |
The purpose of this study is to evaluate the efficacy and safety of alnuctamab compared to standard of care regimens in participants with relapsed or refractory multiple myeloma (RRMM). |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CARDIA Trial | 24-16 | Patients with histologically proven adenocarcinoma of the GEJ type II |
The objective of this study is to compare transthoracic esophagectomy versus transhiatal extended gastrectomy inpatients in patients with adenocarcinoma of the gastroesophageal junction (GEJ) type II |